EHMT1 Gene Therapy for Kleefstra Syndrome Enters Preclinical Collaboration

IDefine–The Kleefstra Syndrome Foundation and UT Southwestern Medical Center have entered a 2-year research collaboration to evaluate a preclinical EHMT1 gene replacement strategy for Kleefstra syndrome, a rare neurodevelopmental disorder with no appoved disease-modifying therapy.¹ The program is expected to run through April 2028 and will be led by Steven Gray, PhD, professor at UT Southwestern and director of the UTSW Gene Therapy Program.

“This landmark research collaboration represents a meaningful step forward in our mission to accelerate research that can lead to a first treatment for Kleefstra syndrome,” said Eric Scheeff, PhD, chief scientific officer of IDefine, in the announcement.¹ The collaboration is notable because it moves a genetically defined neurodevelopmental syndrome into a structured preclinical gene therapy program, but it remains early stage, with no clinical efficacy or human safety data yet reported.

What will the collaboration evaluate?

Under the agreement, IDefine will provide approximately $310,000 to support preclinical research at UT Southwestern focused on feasibility and safety of replacing EHMT1, the gene implicated in Kleefstra syndrome.¹ According to the announcement, the research will use next-generation gene delivery technology designed to target the central nervous system.

The program is not a clinical trial and has not been described as having an investigational new drug application or regulatory submission. The stated objectives are to assess whether an EHMT1 gene replacement approach can be designed and delivered in a way that prioritizes safety and appropriate regulation of gene expression.¹ Those issues are central in neurodevelopmental gene therapy because both insufficient and excessive expression of dosage-sensitive genes may carry biologic risk.

“Advances in gene therapy and CNS-targeted delivery technologies are creating new opportunities to develop potential treatments for complex neurodevelopmental disorders like Kleefstra syndrome,” Gray said in the announcement. “Through this collaboration, we aim to evaluate a carefully designed EHMT1 gene replacement approach while prioritizing safety and appropriate regulation of gene expression.”¹

Why does Kleefstra syndrome need new therapies?

Kleefstra syndrome is caused by pathogenic variants or deletions involving EHMT1, which encodes euchromatic histone lysine methyltransferase 1, a chromatin-modifying enzyme involved in transcriptional regulation during development.^2,3 EHMT1 haploinsufficiency is considered the primary molecular mechanism underlying the syndrome.^2,3

Clinically, the disorder is associated with variable neurodevelopmental manifestations, including intellectual disability, speech impairment, hypotonia, seizures, and behavioral challnges, with severity ranging from mild to profound.^1,2 Current care is supportive and multidisciplinary, typically directed at developmental needs, neurologic complications, behavioral symptoms, feeding or sleep issues, and other organ-system findings when present.² No approved therapy addresses the underlying genetic cause, according to the foundation’s announcement.¹

For biopharmaceutical researchers, Kleefstra syndrome reflects a broader challenge in rare neurodevelopmental disease: the causal gene is known, but therapeutic development must address timing of intervention, CNS biodistribution, cell-type targeting, durability, immune response, and gene-dosage control. FDA guidance for rare disease gene therapy development emphasizes that small populations, limited natural history data, and uncertainty about clinically meaningful end points can complicate preclinical-to-clinical translation.⁴

What are the next steps for EHMT1 gene therapy?

The immediate next step is completion of the preclinical program, including feasibility and safety studies sufficient to determine whether further development is justified. The announcement did not specify the vector platform, route of administration, animal models, planned biomarkers, or criteria for advancing toward clinical testing.¹ Those omissions limit interpretation of the program’s translational readiness.

If the approach advances, future development would likely require a more detailed natural history framework, validated or fit-for-purpose clinical outcome measures, and careful selection of age groups most likely to benefit. In neurodevelopmental disorders, the timing of therapeutic intervention may be especially important because some neurologic features arise during early brain development.

The collaboration also illustrates the growing role of patient advocacy organizations in de-risking early rare disease research. However, the clinical implications should be viewed cautiously until preclinical results are disclosed and reviewed. At present, the program establishes a research pathway for EHMT1 replacement rather than evidence of therapeutic benefit.

References

1. IDefine and UT Southwestern announce research collaboration to advance gene therapy for rare disease Kleefstra syndrome. (2026 Jun 3). PR Newswire. https://www.prnewswire.com/news-releases/idefine-and-ut-southwestern-announce-research-collaboration-to-advance-gene-therapy-for-rare-disease-kleefstra-syndrome-302789121.html
2. Kleefstra T, de Leeuw N. Kleefstra Syndrome. In: Adam MP, Feldman J, Mirzaa GM, et al., eds. GeneReviews®. https://www.ncbi.nlm.nih.gov/books/NBK47079/
3. Kleefstra T, Brunner HG, Amiel J, et al. (2006 Aug). Loss-of-function mutations in euchromatin histone methyl transferase 1 (EHMT1) cause the 9q34 subtelomeric deletion syndrome. Am J Hum Genet. https://pubmed.ncbi.nlm.nih.gov/16826528/
4. US Food and Drug Administration. (2020 Jan). Human Gene Therapy for Rare Diseases: Guidance for Industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-rare-diseases